Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Core Insights - Hummingbird Bioscience has initiated a Phase I clinical trial for HMBD-501, a HER3-targeted antibody-drug conjugate (ADC) designed for advanced HER3-expressing solid malignancies [1][2] Group 1: Clinical Trial Details - The first patient has been dosed in the Phase I clinical trial, which is being conducted at multiple sites in the U.S. [1][2] - Initial data from the dose escalation phase of the trial is expected to be available in the second half of 2026 [4] Group 2: Product Information - HMBD-501 features an exatecan payload optimized for safety and efficacy, aiming to enhance the therapeutic profile compared to previous generation ADCs [2][5] - The product is developed using Hummingbird Bioscience's proprietary antibody discovery and engineering platform, indicating a potential best-in-class status among HER3-targeted ADCs [5] Group 3: Company Overview - Hummingbird Bioscience focuses on discovering and developing transformative medicines for hard-to-treat diseases, leveraging artificial intelligence and human innovation [6] - The company has a pipeline of innovative clinical-stage monoclonal antibodies and ADCs, particularly in oncology and autoimmunity [6]